Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.A. Matters on the agenda of the General Meeting At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the ClinicLund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) today announces preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting, taking place virtually and in-person on November 12[th] – 14[th], 2021 in Washington D.C. The poster highlights preclinical datasets as an overview of the potential indication landscape,

Fiskars Corporation - Notification of management's transactions - Ahlström (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET  Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Ahlström, Anja NathaliePosition: Chief Executive OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number:

Fiskars Corporation - Notification of management's transactions - Siitonen (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET  Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Siitonen, JussiPosition: Chief Financial OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number: 743700BKTW4EQIVKYY42_

High acquisition pace brought strong growth

Third quarter 2021 · Net revenue increased by 28% to SEK 577 million (450). · Adjusted EBITA increased to SEK 82 million (76), corresponding to an adjusted EBITA margin of 14.2% (16.8). · EBIT amounted to SEK 11 million (73). · Adjusted EBIT amounted to SEK 69 million (73). · Adjusted profit for the period amounted to SEK 4 million (27). · Earnings per share, basic and diluted, totalled SEK -0.45 (0.24). · Cash flow from operating activities amounted to SEK 43 million (38). Costs affecting comparability amounted to SEK 58 million (0) in the third quarter of 2021

Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results

Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met its safety and efficacy endpoints also for these dose ranges, and thus for the study in its entirety.COUGH-1 headline results Positive initial data from the first-in-human study of ABNCoV2, the capsid virus like particle (

Autoliv investing in Japan to optimize footprint for future growth

(Stockholm, Sweden, November 12, 2021) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced the launch of a Japan footprint optimization plan, including the establishment of a new state of the art production facility in central Japan and phasing out two existing plants. The investment demonstrates Autoliv’s commitment to its customers and to the Japanese market. Supported by Autoliv’s strong engineering and manufacturing capabilities in Japan, we have gained a leading position with Japanese car manufactures across the world. In

K-Fastigheter strengthens Group Management

K-Fast Holding AB (“K-Fastigheter”) has today appointed Magnus Persson as a new member of Group Management.Magnus Persson has been Business Development manager since May 2021, which includes responsibility for identifying building rights as well as executing transactions. Magnus has previously had the same role in BoKlok/Skanska, where he was also a member of BoKlok’s Swedish management team. Magnus Persson has also worked for, among others, Länsförsäkringar fastighetsförmedling, Modulenthus and NCC.  For more information, please contact:Jacob Karlsson, CEO, e-mail: jacob.karlsson@k-

BioStock: Elicera Therapeutics enters agreement with BioNTech

Elicera Therapeutics’ push to develop novel immuno-oncology therapies just received a significant boost. The company has entered into a collaboration with the German contract development and manufacturing organisation BioNTech for the development of viral vectors to be used in Elicera’s ELC-401 project. Elicera expects to initiate a phase I/II trial with the CAR T-cell candidate in glioblastoma multiforme patients during the second half of 2023.Read the article at biostock.se: https://www.biostock.se/en/2021/11/elicera-therapeutics-enters-agreement-with-biontech/ This is a press

MPC Container Ships ASA announces date for Q3 and nine-month 2021 results

Oslo, 12 November 2021 - MPC Container Ships ASA (the "Company") will be releasing its third quarter 2021 report prior to market opening on Thursday 18 November 2021. The Company will host a webcast for the presentation of the Q3 2021 results commencing on Thursday 18 November 2021 at 15:00 hours CET / 09:00 hours EDT. The presentation will be made available on the Company’s webpage from 12:00 hours CET / 06:00 hours EDT. There will be a Q&A session after the presentation. The event is being streamed. It is recommended that you

Enfo Group’s interim report Q3 July 1 – September 30, 2021

Enfo Q3/2021: Net sales improvedQ3/2021 · Net sales during July–September were EUR 23.1 (21.4) million · EBITDA was EUR 1.9 (1.3) million · Operating profit (EBIT) was EUR -0.3 (-1.0) million · Profit for the period was EUR -0.7 (-1.1) million · Earnings per share were EUR -1.0 (-1.5) · Operating cash flow was EUR -0.7 (1.0) million Q1-Q3/2021 · Net sales during January–September were EUR 76.4 (74.8) million · EBITDA was EUR 5.2 (5.0) million · Operating profit (EBIT) was EUR -2.3 (-1.8) million · Profit for the period was EUR -3.5 (-2.9) million  ·

AZN: Year to date and Q3 2021 results

AstraZeneca PLC 12 November 2021 07:00 GMT Year to date and Q3 2021 results AstraZeneca reinforces its scientific leadership through exceptionalpipeline delivery and the addition of Alexion in the quarter -    Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% (28% at CER). Total Revenue in the third quarter increased by 50% (48% at CER) to $9,866m -    Excluding the pandemic COVID-19 vaccine, Total Revenue increased 21% (17% at CER) in the year to date to $23,187m, and by 34% (32% at CER) in the quarter to $8,

North Investment Group AB - Q3 2021

Q3 2021 Interim financial reportFINANCIAL HIGHLIGHTS  · Group revenue of SEK 203.1m (SEK 186.6m). · Gross profit margin 38.6% (38.5%). · EBITDA of SEK 29.8m (SEK 30.2m). · Net operating cash flow SEK 24.7m (SEK 32.5m). · 3PL services in Sweden established with success. · Corporate bond listed on Nasdaq Stockholm 2[nd] November. · Freight prices and raw material prices still on historic high level. · Merge in Sweden finalized 1[st] November. · Order backlog of SEK 138.4m (SEK 85.3m).

Hansa Biopharma Nomination Committee formed

Lund November 12, 2021. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on May 12, 2021 and has the following composition: · Natalie Berner representing Redmile Group · Lotta Sjöberg representing Handelsbanken Fonder  · Jannis Kitsakis representing AP4 As the conveyer of the Nomination Committee, Ulf Wiinberg, Chairman of the Board of Directors at Hansa Biopharma will be asked to summon the first meeting in the Nomination Committee. The function of the Nomination

Remedy Entertainment Plc: Q3 Business Review: Business progressed as planned, outlook unchanged

Remedy Entertainment Plc | Company announcement 09:00 am (EET) 12 November 2021BUSINESS REVIEW January– September 2021 (unaudited) Business progressed as planned, outlook unchanged Alan Wake Remastered announced and completed for launch HIGHLIGHTS IN JULY–SEPTEMBER 2021 · Revenue was 7 398 (9 914) thousand euros and decreased -25.4 % year-on-year primarily due to a decline in Control royalties and reduced development fees from our Smilegate partnership. · Operating profit (EBIT) was 290 (3 443) thousand euros. The decrease was mainly due to a very strong comparison period

K-Fast Holding AB (publ): Interim report January–September 2021

Financial ratios for the period 1 January–30 September 2021     +----------------+---------+---------+---------+---------+--------+|  Financial |    2021 |    2020 |   2021 |    2020 |   2020 ||ratios | Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep |Jan–Dec |+----------------+---------+---------+---------+---------+--------+|  Rental income,| 68.2 | 51.0 | 190.7 |  147.7 |  203.9 ||SEK million | | | | | |+----------------+---------+---------+---------+---------+--------+|  Profit from |  29.8 |  21.2 |

Peab builds nursing home in Oslo

Peab has been commissioned to build the new nursing home Tåsenhjemmet in Oslo. The customer is Oslobygg KF and the contract is worth NOK 446 million.The turnkey contract comprises four floors with 130 private rooms and a daycare center built in solid wood along with a basement. The gross area will be slightly more than 14,000 m2. The new Tåsenhjemmet will be environmentally certified according to BREEAM Excellent and a zero emissions building. The project will also be a so-called FutureBuilt project that promotes climate neutral city development in the Oslo region. “Tåsenhjemmet is a

Sivers Semiconductors AB (publ), Interim Report Q3, January – September 2021

Third quarter 2021 · Revenue amounted to SEK 26.511 M (22.208), an increase of 19% · Profit before depreciation and amortization (EBITDA) amounted to SEK -45.911 M (-38.699) · Operating profit/loss (EBIT) for the period was SEK -53.906 M (-46.030) · Profit/loss after tax was SEK -53.466 M (-151.610) · Earnings per share before and after dilution was SEK -0.34 (-1.07) · Equity per share amounted to SEK 2.75 (2.51) · Profit for the quarter was negatively affected by acquisition costs of SEK 37.371 M relating to the acquisition of MixCommJanuary- September 2021: ·

Kamux Corporation’s Interim Report for January 1 - September 30, 2021

Kamux Corporation                Interim Report                                            November 12, 2021 at 09:00 Kamux Corporation’s Interim Report for January 1 - September 30, 2021 Kamux saw very strong growth, revenue +22.8% - Adjusted operating profit (EBIT) remained below the comparison period The figures in parentheses refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. July-September in brief - Revenue increased by 22.8%, totaling EUR 254.6 million (207.4) - Gross profit increased by 0.4% to EUR 29.0 million (28.9)

Starbreeze AB (publ) Interim Report Q3 2021

Third quarter 2021 · Net sales amounted to SEK 34.7 million (32.1). PAYDAY accounted for SEK 31.2 million (31.1). · EBITDA* amounted to SEK 19.9 million (11.7). · Amortization, depreciation and impairments amounted to SEK 15.0 million (7.8). · Profit before tax was SEK -8.0 million (-8.2). · Basic and diluted earnings per share was SEK -0.01 (-0.02). Nine-month period 2021 · Net sales amounted to SEK 94.6 million (85.4). PAYDAY accounted for SEK 89.6 million (80.8). · EBITDA* amounted to SEK -9.4 million (44.0). · EBITDA**, adjusted for one-off effects related

The subscription period in Alligator Bioscience's rights issue begins today

Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rights issue of shares (the “Rights Issue”) which was resolved by the Board of Directors on 7 October 2021 and approved by the Extraordinary General Meeting held on 8 November 2021. Summary of the Rights Issue · One (1) existing share in the Company entitles to three (3) subscription rights. Two (2) subscription rights entitle to subscription of one (1) new share, i.e., a subscription ratio of 3:2. · The subscription price is SEK 2 per new share, which, assuming

Fortum’s January–September 2021 Interim Report: Strong performance in an exceptional commodity market

FORTUM CORPORATION JANUARY–SEPTEMBER 2021 INTERIM REPORT 12 NOVEMBER 2021 AT 9:00 EET This release is a summary of Fortum’s 2021 January–September 2021 Interim Report. The complete report is attached to this release as a PDF file. It is also available on the company's website at www.fortum.com/investors. July–September 2021 · Comparable EBITDA was EUR 574 (132) million · Comparable operating profit was EUR 260 (-179) million · Operating profit was EUR -3,105 (-1) million, mainly impacted by changes in fair values of non-hedge-accounted derivatives partly offset by capital

There are no items matching the current filter
There are no more items matching the current filter
Back to top